Richardson Financial Services Inc. Has $102,000 Position in Pfizer Inc. (NYSE:PFE)

Richardson Financial Services Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 68.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,867 shares of the biopharmaceutical company’s stock after selling 8,253 shares during the quarter. Richardson Financial Services Inc.’s holdings in Pfizer were worth $102,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter valued at about $26,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP acquired a new stake in Pfizer in the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Pfizer in the third quarter valued at $35,000. Finally, Joseph Group Capital Management lifted its holdings in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.51 on Monday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $150.20 billion, a PE ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. The stock’s fifty day simple moving average is $26.27 and its 200 day simple moving average is $27.86.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 232.44%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Guggenheim dropped their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Finally, Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.